Pacira BioSciences, Inc. Common Stock
PCRXPacira BioSciences, Inc. is a pharmaceutical company specializing in non-opioid, local analgesic products. It is best known for its flagship product, EXPAREL, a long-lasting local anesthetic used for postoperative pain management. The company focuses on developing and commercializing non-opioid pain control options to reduce reliance on opioids and improve patient recovery outcomes.
Company News
Pacira BioSciences received a Paragraph IV Certification Notice from Qilu Pharmaceutical regarding a generic equivalent filing for EXPAREL, challenging 18 of Pacira's patents. Pacira intends to vigorously defend its intellectual property rights.
Pacira BioSciences will present research at AMCP Nexus 2025 highlighting the clinical effectiveness and economic benefits of EXPAREL, a non-opioid pain therapy, with multiple studies focusing on pain management in knee and shoulder surgeries.
Pacira BioSciences granted inducement awards to 15 new employees, including 18,000 stock options and 32,600 restricted stock units, to incentivize new hires under their Inducement Plan.
Pacira BioSciences granted stock options and restricted stock units to nine new employees under its Inducement Plan, with 13,000 stock options and 18,100 restricted stock units awarded.
Pacira BioSciences debuted a new film at the BIO 2025 convention, highlighting the journey of a couple who found relief from chronic pain through non-opioid treatments. The film showcases the impact of innovative pain management solutions and the importance of patients having options beyond opioids.
